research Baricitinib Induced Hypoglycemic Seizures in a Patient with Hair Loss and Type I Diabetes Mellitus: A Case Report
Baricitinib may cause low blood sugar in some patients, so careful monitoring is needed.
Search
for
Sort by
Research
630-660 / 1000+ results research 1343 Efficacy of asymmetric siRNA targeting androgen receptor for the treatment of androgenetic alopecia
cp-asiAR may effectively treat hair loss by targeting androgen receptors.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Discovery of Orally Available Prodrugs of Itaconate and Derivatives
New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research 438 Laminin-511 is a new player in the development of psoriasis and controlled via cannabinoid receptor type 1
Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.
research 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
research Unexpected Effect of Baricitinib Use: Observation of a Case of Hypertrichosis
Baricitinib can cause excessive hair growth.
research Sinapic acid and glabridin synergistically mitigate androgenetic alopecia by modulating ferroptosis through stabilization of β-catenin against ubiquitin-dependent degradation.
Sinapic acid and glabridin together help hair growth in androgenetic alopecia.
research 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
research At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.
research A Hero Revealed: Targeting the AHR for treatment of inflammatory skin diseases
AHR ligands could treat inflammatory skin diseases.
research Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
Interest in JAK inhibitors for alopecia areata increased significantly after FDA approval, highlighting the need for patient education.
research Targeting PrfA from Listeria monocytogenes: a computational drug repurposing approach
The research suggests Dutasteride and Solifenacin may be effective against the bacterium causing listeriosis.
research Mechanistic synergy of hair growth promotion by the Avicennia marina extract and its active constituent (avicequinone C) in dermal papilla cells isolated from androgenic alopecia patients
Avicennia marina extract and avicequinone C can potentially promote hair growth and treat hair loss by interfering with hair loss mechanisms and boosting growth factors.
research Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
research Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
research AMPK Phosphorylates ZDHHC13 to Increase MC1R Activity and Suppress Melanomagenesis
AMPK activation may reduce melanoma risk in red-haired individuals.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats
research Finasteride to treat recurrent priapism in sickle cell anemia
research Alopecia Universalis Successfully Treated With Adalimumab
A woman with severe hair loss was successfully treated with the drug adalimumab.
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
research Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.